135 related articles for article (PubMed ID: 37738672)
21. Semiparametric competing risks regression under interval censoring using the R package intccr.
Park J; Bakoyannis G; Yiannoutsos CT
Comput Methods Programs Biomed; 2019 May; 173():167-176. PubMed ID: 31046992
[TBL] [Abstract][Full Text] [Related]
22. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.
Poguntke I; Schumacher M; Beyersmann J; Wolkewitz M
BMC Med Res Methodol; 2018 Jul; 18(1):79. PubMed ID: 30012114
[TBL] [Abstract][Full Text] [Related]
23. Methods of competing risks flexible parametric modeling for estimation of the risk of the first disease among HIV infected men.
Nouri S; Mahmoudi M; Mohammad K; Mansournia MA; Yaseri M; Akhtar-Danesh N
BMC Med Res Methodol; 2020 Jan; 20(1):17. PubMed ID: 31996148
[TBL] [Abstract][Full Text] [Related]
24. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.
Perego C; Sbolli M; Specchia C; Fiuzat M; McCaw ZR; Metra M; Oriecuia C; Peveri G; Wei LJ; O'Connor CM; Psotka MA
JACC Heart Fail; 2020 Dec; 8(12):973-983. PubMed ID: 33039446
[TBL] [Abstract][Full Text] [Related]
25. Doubly-robust estimator of the difference in restricted mean times lost with competing risks data.
Lin J; Trinquart L
Stat Methods Med Res; 2022 Oct; 31(10):1881-1903. PubMed ID: 35607287
[TBL] [Abstract][Full Text] [Related]
26. Prediction accuracy and variable selection for penalized cause-specific hazards models.
Saadati M; Beyersmann J; Kopp-Schneider A; Benner A
Biom J; 2018 Mar; 60(2):288-306. PubMed ID: 28762523
[TBL] [Abstract][Full Text] [Related]
27. Association of pathogen-specific clinical mastitis in the first 100 days of first lactation with productive lifetime: An observational study comparing competing risks models for death and sale with the Cox model.
Hertl JA; Schukken YH; Tauer LW; Welcome FL; Gröhn YT
Prev Vet Med; 2023 Apr; 213():105879. PubMed ID: 36841041
[TBL] [Abstract][Full Text] [Related]
28. Linear and nonlinear variable selection in competing risks data.
Ren X; Li S; Shen C; Yu Z
Stat Med; 2018 Jun; 37(13):2134-2147. PubMed ID: 29579776
[TBL] [Abstract][Full Text] [Related]
29. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
Geskus RB
Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
[TBL] [Abstract][Full Text] [Related]
30. Vertical modelling: Analysis of competing risks data with missing causes of failure.
Nicolaie MA; van Houwelingen HC; Putter H
Stat Methods Med Res; 2015 Dec; 24(6):891-908. PubMed ID: 22179822
[TBL] [Abstract][Full Text] [Related]
31. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes.
Lim HJ; Zhang X; Dyck R; Osgood N
BMC Med Res Methodol; 2010 Oct; 10():97. PubMed ID: 20964855
[TBL] [Abstract][Full Text] [Related]
32. Planning and analyzing clinical trials with competing risks: Recommendations for choosing appropriate statistical methodology.
Poythress JC; Lee MY; Young J
Pharm Stat; 2020 Jan; 19(1):4-21. PubMed ID: 31625290
[TBL] [Abstract][Full Text] [Related]
33. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
[TBL] [Abstract][Full Text] [Related]
34. Tree-based models for survival data with competing risks.
Kretowska M
Comput Methods Programs Biomed; 2018 Jun; 159():185-198. PubMed ID: 29650312
[TBL] [Abstract][Full Text] [Related]
35. Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.
Yang Q; Fung WK; Li G
Stat Med; 2018 Apr; 37(8):1389-1401. PubMed ID: 29282764
[TBL] [Abstract][Full Text] [Related]
36. Sample size calculations in the presence of competing risks.
Latouche A; Porcher R
Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
[TBL] [Abstract][Full Text] [Related]
37. Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple Fine-Gray Subdistribution Hazard Models.
Austin PC; Putter H; Lee DS; Steyerberg EW
Circ Cardiovasc Qual Outcomes; 2022 Feb; 15(2):e008368. PubMed ID: 35098725
[TBL] [Abstract][Full Text] [Related]
38. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
39. On the relation between the cause-specific hazard and the subdistribution rate for competing risks data: The Fine-Gray model revisited.
Putter H; Schumacher M; van Houwelingen HC
Biom J; 2020 May; 62(3):790-807. PubMed ID: 32128860
[TBL] [Abstract][Full Text] [Related]
40. Misspecified regression model for the subdistribution hazard of a competing risk.
Latouche A; Boisson V; Chevret S; Porcher R
Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
